Alimera Sciences

$4.74
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.09 (+1.94%) Today
$0.00 (0.00%) As of 6:00 PM EST after-hours

Why Robinhood?

You can buy or sell ALIM and other stocks, options, and ETFs commission-free!

About ALIM

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA. The listed name for ALIM is Alimera Sciences, Inc. Common Stock.

CEO
Richard S. Eiswirth
Employees
127
Headquarters
Alpharetta, Georgia
Founded
2003
Market Cap
24.32M
Price-Earnings Ratio
Dividend Yield
Average Volume
50.85K
High Today
$4.75
Low Today
$4.63
Open Price
$4.67
Volume
23.20K
52 Week High
$9.98
52 Week Low
$2.86

Collections

ALIM Earnings

-$1.44
-$0.93
-$0.43
$0.08
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 24, After Hours

You May Also Like